Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C21H26N2O |
| Molecular Weight | 322.4439 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN([C@H](CN1CCCC1)C2=CC=CC=C2)C(=O)CC3=CC=CC=C3
InChI
InChIKey=OVZWUDZIAAHNFG-HXUWFJFHSA-N
InChI=1S/C21H26N2O/c1-22(21(24)16-18-10-4-2-5-11-18)20(17-23-14-8-9-15-23)19-12-6-3-7-13-19/h2-7,10-13,20H,8-9,14-17H2,1H3/t20-/m1/s1
| Molecular Formula | C21H26N2O |
| Molecular Weight | 322.4439 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/8071934Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/15863335 | https://google.com/patents/WO1998049141A1
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8071934
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/15863335 | https://google.com/patents/WO1998049141A1
N-MPPP HYDROCHLORIDE is high-affinity κ agonist with no measured binding at μ or δ sites.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL237 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15863335 |
5.8 nM [Ki] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
Sources: https://google.com/patents/WO1998049141A1 |
Primary | Unknown Approved UseUnknown |
||
Sources: https://google.com/patents/WO1998049141A1 |
Primary | Unknown Approved UseUnknown |
||
Sources: https://google.com/patents/WO1998049141A1 |
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8071934
Hartley-VAF Plus guinea pigs were killed by decapitation and the brains removed. The brains, less cerebellum, were homogenized in six volumes of 0.05 M Trizma buffer (pH 7.4) with a Virtrishear homogenizer at a control setting of 70 for three 5 s intervals. The homogenate was centrifuged at 25000g at 40C for 20 min. The pellet was resuspended in six volumes of aqueous 0.32 M sucrose and stored at -70 0C until needed. Frozen homogenate was thawed at room temperature and diluted with 0.05 M Trizma buffer (pH 7.4) to give a final dilution ratio of 1:60 (initial brain weight to total solution volume). Radioligands used were [3H]bremazocine (0.5 nM) for total ligand binding, [3H]DAMG0 (1.0 nM) for preceptor binding, [3H]DPDPE (1.0 nM) for delta- receptor binding, and [3H]U-69,593( 1.0 nM) for kapa-receptor N-MPPP was tested against bremazocine and DPDPE in duplicate at nine concentrations between 1.0 and 1000 nM, N-MPPP tested against [3H]U-69,593 in triplicate at five concentrations between 0.22 and 4.7 nM. Nonspecific binding was measured in the presence of 10 mkM naloxone
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 23:07:42 GMT 2025
by
admin
on
Mon Mar 31 23:07:42 GMT 2025
|
| Record UNII |
0G3RS2P5HF
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID90935832
Created by
admin on Mon Mar 31 23:07:42 GMT 2025 , Edited by admin on Mon Mar 31 23:07:42 GMT 2025
|
PRIMARY | |||
|
157947-87-0
Created by
admin on Mon Mar 31 23:07:42 GMT 2025 , Edited by admin on Mon Mar 31 23:07:42 GMT 2025
|
PRIMARY | |||
|
190901
Created by
admin on Mon Mar 31 23:07:42 GMT 2025 , Edited by admin on Mon Mar 31 23:07:42 GMT 2025
|
PRIMARY | |||
|
0G3RS2P5HF
Created by
admin on Mon Mar 31 23:07:42 GMT 2025 , Edited by admin on Mon Mar 31 23:07:42 GMT 2025
|
PRIMARY |